The Trump administration canceled a Biden-era plan on Friday that would have made Ozempic and other weight-loss drugs ...

Fetterman appealed to President Trump and Health and Human Services Secretary Robert F. Kennedy Jr. personally.

In a New York Times column this week, the Pennsylvania Democrat shared his experience taking Mounjaro while advocating for ...

As discussions unfold, Kennedy seeks to balance drug accessibility with concerns about the long-term costs of providing GLP-1 ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Medicare does cover GLP-1 drugs when prescribed for conditions ... Kennedy Jr. has criticized GLP-1 medications like Ozempic ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

In this week’s edition of InnovationRx, we look at the impact of Medicaid cuts, a $400 million obesity bet, a study of bias ...

The Trump administration announced Friday it will not move forward with plans to cover popular weight-loss drugs under ...

The Centers for Medicare & Medicaid Services will not cover drugs when exclusively used for weight loss, like Ozempic or ...